David S Liebeskind Selected Research

Neuroprotective Agents

7/2023	Circadian variation in stroke onset: Differences between ischemic and hemorrhagic stroke and weekdays versus weekends.
1/2023	APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke.
1/2022	Beyond the Golden Hour: Treating Acute Stroke in the Platinum 30 Minutes.
1/2022	Quantifying the amount of greater brain ischemia protection time with pre-hospital vs. in-hospital neuroprotective agent start.
2/2014	Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 2 - prehospital study methods.
2/2014	Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 1 - rationale and general methods.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David S Liebeskind Research Topics

Disease

246	Stroke (Strokes) 05/2024 - 01/2003
168	Ischemic Stroke 05/2024 - 01/2002
43	Infarction (Infarctions) 05/2024 - 09/2007
28	Pathologic Constriction (Stenosis) 04/2023 - 05/2010
20	Intracranial Hemorrhages (Intracranial Hemorrhage) 02/2024 - 10/2007
19	Brain Ischemia (Cerebral Ischemia) 01/2023 - 03/2004
15	Cerebral Infarction 04/2023 - 04/2002
14	Ischemia 01/2023 - 02/2008
12	Hemorrhage 02/2024 - 04/2007
12	Hypertension (High Blood Pressure) 01/2023 - 05/2007
11	Arterial Occlusive Diseases (Arterial Occlusive Disease) 11/2023 - 12/2002
9	Cerebral Hemorrhage 05/2024 - 01/2002
9	Thrombosis (Thrombus) 10/2023 - 03/2012
8	Atrial Fibrillation 01/2023 - 01/2006
8	COVID-19 02/2022 - 01/2020
7	Hematoma 12/2023 - 02/2012
7	Intracranial Arteriosclerosis (Cerebral Atherosclerosis) 08/2018 - 01/2012
7	Cerebrovascular Disorders (Cerebrovascular Occlusion) 05/2017 - 10/2009
6	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2024 - 09/2010
6	Transient Ischemic Attack 01/2022 - 08/2006
5	Atherosclerosis 05/2024 - 01/2008
5	Embolic Stroke 01/2023 - 01/2013
5	Embolism (Embolus) 02/2021 - 12/2009
5	Neurologic Manifestations (Neurological Manifestations) 11/2020 - 01/2008
5	Hyperlipidemias (Hyperlipidemia) 10/2016 - 01/2009
4	Inflammation (Inflammations) 11/2023 - 01/2017
3	Edema (Dropsy) 01/2024 - 11/2021
3	Brain Injuries (Brain Injury) 11/2023 - 01/2015
3	Reperfusion Injury 01/2023 - 09/2013
3	Venous Thrombosis (Deep-Vein Thrombosis) 09/2022 - 09/2014
3	Heart Failure 01/2021 - 11/2016
3	Diabetes Mellitus 10/2016 - 05/2007
2	Cognitive Dysfunction 05/2024 - 01/2021
2	Seizures (Absence Seizure) 11/2023 - 08/2005
2	Patent Foramen Ovale 01/2023 - 05/2007
2	Brain Diseases (Brain Disorder) 09/2022 - 01/2018
2	Thrombophilia 01/2021 - 01/2014
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 12/2010
2	Myocardial Infarction 09/2013 - 06/2011
1	Cerebral Small Vessel Diseases 05/2024
1	Aneurysm (Aneurysms) 05/2024
1	Body Weight (Weight, Body) 02/2024
1	Wounds and Injuries (Trauma) 11/2023
1	Epilepsy (Aura) 11/2023

Drug/Important Bio-Agent (IBA)

25	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2023 - 10/2007
21	MagnesiumIBA 12/2023 - 01/2009
18	Biomarkers (Surrogate Marker)IBA 05/2024 - 05/2008
14	Phenobarbital (Luminal)FDA Link 10/2023 - 05/2010
12	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 05/2007
9	Cytidine Triphosphate (CTP)IBA 11/2023 - 02/2016
7	AnticoagulantsIBA 05/2024 - 10/2016
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 08/2006
6	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 12/2023 - 02/2014
6	Blood Glucose (Blood Sugar)IBA 11/2023 - 06/2011
6	Neuroprotective AgentsIBA 07/2023 - 02/2014
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2005
5	Fibrinolytic Agents (Antithrombotic Agents)IBA 02/2024 - 04/2002
5	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 06/2011
4	LipidsIBA 01/2023 - 01/2014
3	CytokinesIBA 05/2024 - 11/2008
3	Tenecteplase FDA Link 02/2024 - 10/2018
3	oxidized low density lipoproteinIBA 01/2022 - 01/2015
3	CholesterolIBA 01/2022 - 08/2006
3	antineoplaston A10 (A 10)IBA 01/2021 - 01/2012
3	Heparin (Liquaemin)FDA LinkGeneric 01/2021 - 07/2018
3	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 01/2006
3	Indicators and Reagents (Reagents)IBA 12/2018 - 02/2012
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2014 - 06/2011
2	LDL CholesterolIBA 01/2023 - 01/2022
2	Contrast MediaIBA 01/2023 - 01/2009
2	salicylhydroxamic acid (SHAM)IBA 12/2022 - 11/2017
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 10/2009
2	Complement System Proteins (Complement)IBA 01/2021 - 09/2007
2	Dihydrotachysterol (AT 10)IBA 10/2020 - 12/2015
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2020 - 01/2008
2	Amyloid (Amyloid Fibrils)IBA 01/2020 - 01/2014
2	Vitamin K FDA Link 01/2017 - 01/2017
2	HomocysteineIBA 01/2010 - 10/2009
2	ElementsIBA 02/2008 - 08/2006
1	Interleukin-18 (Interleukin 18)IBA 05/2024
1	Anesthetics (Anesthetic Agents)IBA 04/2024
1	TM5441IBA 01/2024
1	InterleukinsIBA 11/2023

Therapy/Procedure

177	Therapeutics 05/2024 - 12/2002
115	Thrombectomy 05/2024 - 04/2007
22	Stents 02/2024 - 06/2011
13	Precision Medicine 11/2021 - 01/2014
8	Punctures 01/2022 - 09/2013
8	Thrombolytic Therapy 12/2021 - 01/2002
7	Catheters 01/2022 - 08/2008
4	Endovascular Procedures 05/2024 - 01/2009
4	Secondary Prevention 01/2023 - 08/2006
4	Time-to-Treatment 03/2022 - 11/2011
4	Treatment Delay 02/2022 - 01/2015
4	General Anesthesia 01/2020 - 06/2010
4	Embolectomy 01/2017 - 01/2009
3	Length of Stay 01/2021 - 03/2007
2	Transcranial Direct Current Stimulation 01/2023 - 01/2022
2	Radiotherapy 12/2022 - 02/2013
2	Aftercare (After-Treatment) 01/2019 - 08/2014